A

Aelis Farma SA
PAR:AELIS

Watchlist Manager
Aelis Farma SA
PAR:AELIS
Watchlist
Price: 2.98 EUR Market Closed
Market Cap: 40.8m EUR
Have any thoughts about
Aelis Farma SA?
Write Note

Intrinsic Value

The intrinsic value of one AELIS stock under the Base Case scenario is 1.39 EUR. Compared to the current market price of 2.98 EUR, Aelis Farma SA is Overvalued by 54%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AELIS Intrinsic Value
1.39 EUR
Overvaluation 54%
Intrinsic Value
Price
A
Base Case Scenario

Valuation Backtest
Aelis Farma SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AELIS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AELIS?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Aelis Farma SA

Provide an overview of the primary business activities
of Aelis Farma SA.

What unique competitive advantages
does Aelis Farma SA hold over its rivals?

What risks and challenges
does Aelis Farma SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Aelis Farma SA.

Provide P/S
for Aelis Farma SA.

Provide P/E
for Aelis Farma SA.

Provide P/OCF
for Aelis Farma SA.

Provide P/FCFE
for Aelis Farma SA.

Provide P/B
for Aelis Farma SA.

Provide EV/S
for Aelis Farma SA.

Provide EV/GP
for Aelis Farma SA.

Provide EV/EBITDA
for Aelis Farma SA.

Provide EV/EBIT
for Aelis Farma SA.

Provide EV/OCF
for Aelis Farma SA.

Provide EV/FCFF
for Aelis Farma SA.

Provide EV/IC
for Aelis Farma SA.

Show me price targets
for Aelis Farma SA made by professional analysts.

What are the Revenue projections
for Aelis Farma SA?

How accurate were the past Revenue estimates
for Aelis Farma SA?

What are the Net Income projections
for Aelis Farma SA?

How accurate were the past Net Income estimates
for Aelis Farma SA?

What are the EPS projections
for Aelis Farma SA?

How accurate were the past EPS estimates
for Aelis Farma SA?

What are the EBIT projections
for Aelis Farma SA?

How accurate were the past EBIT estimates
for Aelis Farma SA?

Compare the revenue forecasts
for Aelis Farma SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Aelis Farma SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Aelis Farma SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Aelis Farma SA compared to its peers.

Compare the P/E ratios
of Aelis Farma SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Aelis Farma SA with its peers.

Analyze the financial leverage
of Aelis Farma SA compared to its main competitors.

Show all profitability ratios
for Aelis Farma SA.

Provide ROE
for Aelis Farma SA.

Provide ROA
for Aelis Farma SA.

Provide ROIC
for Aelis Farma SA.

Provide ROCE
for Aelis Farma SA.

Provide Gross Margin
for Aelis Farma SA.

Provide Operating Margin
for Aelis Farma SA.

Provide Net Margin
for Aelis Farma SA.

Provide FCF Margin
for Aelis Farma SA.

Show all solvency ratios
for Aelis Farma SA.

Provide D/E Ratio
for Aelis Farma SA.

Provide D/A Ratio
for Aelis Farma SA.

Provide Interest Coverage Ratio
for Aelis Farma SA.

Provide Altman Z-Score Ratio
for Aelis Farma SA.

Provide Quick Ratio
for Aelis Farma SA.

Provide Current Ratio
for Aelis Farma SA.

Provide Cash Ratio
for Aelis Farma SA.

What is the historical Revenue growth
over the last 5 years for Aelis Farma SA?

What is the historical Net Income growth
over the last 5 years for Aelis Farma SA?

What is the current Free Cash Flow
of Aelis Farma SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Aelis Farma SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Aelis Farma SA

Balance Sheet Decomposition
Aelis Farma SA

Current Assets 38.6m
Cash & Short-Term Investments 34.4m
Receivables 3.9m
Other Current Assets 347k
Non-Current Assets 616k
PP&E 176k
Intangibles 190k
Other Non-Current Assets 250k
Current Liabilities 15.8m
Accounts Payable 2.4m
Accrued Liabilities 668k
Other Current Liabilities 12.7m
Non-Current Liabilities 3.6m
Long-Term Debt 1.4m
Other Non-Current Liabilities 2.3m
Efficiency

Earnings Waterfall
Aelis Farma SA

Revenue
7.6m EUR
Operating Expenses
-15.2m EUR
Operating Income
-7.7m EUR
Other Expenses
658k EUR
Net Income
-7m EUR

Free Cash Flow Analysis
Aelis Farma SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

AELIS Profitability Score
Profitability Due Diligence

Aelis Farma SA's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

Exceptional 1-Year Revenue Growth
Negative Operating Income
Negative Net Income
Negative ROE
17/100
Profitability
Score

Aelis Farma SA's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

AELIS Solvency Score
Solvency Due Diligence

Aelis Farma SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
High Altman Z-Score
Short-Term Solvency
63/100
Solvency
Score

Aelis Farma SA's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AELIS Price Targets Summary
Aelis Farma SA

Wall Street analysts forecast AELIS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AELIS is 15.3 EUR with a low forecast of 15.15 EUR and a high forecast of 15.75 EUR.

Lowest
Price Target
15.15 EUR
408% Upside
Average
Price Target
15.3 EUR
413% Upside
Highest
Price Target
15.75 EUR
429% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AELIS?

Click here to dive deeper.

Dividends

Aelis Farma SA
does not pay dividends
Shareholder Yield

Current shareholder yield for AELIS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Aelis Farma SA

Country

France

Industry

Biotechnology

Market Cap

37.2m EUR

Dividend Yield

0%

Description

Aelis Farma SA develops biotechnology solutions. The company is headquartered in Bordeaux, Nouvelle-Aquitaine and currently employs 24 full-time employees. The company went IPO on 2022-02-18. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.

Contact

NOUVELLE-AQUITAINE
Bordeaux
Neurocentre Francois Magendie 146 Rue Leo, Saignat
+33557573770
www.aelisfarma.com

IPO

2022-02-18

Employees

24

Officers

CEO & Director
Dr. Pier Vincenzo Piazza M.D., Ph.D.
Head of Finance
Ms. Marie Line Lefevre
Chief Operating Officer
Stephanie Monlezun
Head of Legal
Ms. Lea Floquet
Chief Corporate Development Officer
Mr. Arsene Guekam
Head of Discovery & IP Leader
Ms. Sandy Fabre
Show More
Head of Preclinical Development
Ms. Aurelie Boucard
Head of Clinical Development
Ms. Helle Mengel
Head of Pharmaceutical Development
Ms. Corinne Chaimbault
Show Less

See Also

Discover More
What is the Intrinsic Value of one AELIS stock?

The intrinsic value of one AELIS stock under the Base Case scenario is 1.39 EUR.

Is AELIS stock undervalued or overvalued?

Compared to the current market price of 2.98 EUR, Aelis Farma SA is Overvalued by 54%.

Back to Top